Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers

Authors: Preeti Putcha, Jiyang Yu, Ruth Rodriguez-Barrueco, Laura Saucedo-Cuevas, Patricia Villagrasa, Eva Murga-Penas, Steven N. Quayle, Min Yang, Veronica Castro, David Llobet-Navas, Daniel Birnbaum, Pascal Finetti, Wendy A. Woodward, François Bertucci, Mary L. Alpaugh, Andrea Califano, Jose Silva

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

After the publication of this article [1] the authors noticed two small mistakes in the affiliations listings
1)
Dr. Ruth Rodriguez should be marked as an equal contributor alongside Dr. Putcha and Dr. Yu.
 
2)
Dr. Ruth Rodriguez’s correct affiliation is ‘Department of Pathology, Icahn School of Medicine at Mount Sinai , New York, NY 10029-6574, USA’ and not ‘Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA’ as the original article states.
 
Literature
1.
go back to reference Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res. 2015;17:149. doi:10.1186/s13058-015-0658-0.CrossRefPubMedPubMedCentral Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res. 2015;17:149. doi:10.​1186/​s13058-015-0658-0.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
Authors
Preeti Putcha
Jiyang Yu
Ruth Rodriguez-Barrueco
Laura Saucedo-Cuevas
Patricia Villagrasa
Eva Murga-Penas
Steven N. Quayle
Min Yang
Veronica Castro
David Llobet-Navas
Daniel Birnbaum
Pascal Finetti
Wendy A. Woodward
François Bertucci
Mary L. Alpaugh
Andrea Califano
Jose Silva
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0841-6

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine